03:31 EDT 26th August 2019 | BioPortfolio

Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosimilars and consumer health (including over--the-counter medications).

The main pharmaceutical focus is on medications for the following areas of disease; Cardiovascular and Metabolism, Oncology (including Hematology), Neuroscience and Ophthalmics, Respiratory and Immunology and Infectious Diseases; and the portfolio contains over 50 key products. 147 products are in the pipeline.

Over 20 vaccines have been developed by Novartis, including influenza, meningitis, polio and tetanus, and the company is also developing diagnostic mechanisms for blood and protection of possible blood infections, which is used by 80% of US blood banks.  Sandoz, a sub-group, has a broad portfolio helping to make affordable, high-quality medicines available to patients around the world and stabilize healthcare systems.

Source; and

Add the Novartis News Channel to your RSS reader;

Follow the Novartis Twitter feed;

Quick Search

review and buy Novartis market research data and corporate reports here